Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tegoprazan + naproxen
- Development stage
- Phase 1
- Lead developer
- HK inno.N Corporation
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IN-M00002 is a fixed-dose combination (FDC) tablet containing tegoprazan and naproxen, developed by HK inno.N Corporation. Tegoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits gastric acid secretion by competitively blocking the potassium-binding site of the H+/K+-ATPase enzyme in gastric parietal cells. Naproxen is a non-selective non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes to provide analgesic and anti-inflammatory effects. This combination is designed to provide effective pain relief while reducing the risk of NSAID-induced gastric ulcers by maintaining a higher gastric pH. It is currently in Phase 1 clinical development for the treatment of pain and the prevention of gastric ulcers.
- Other names
- tegoprazan/naproxen
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on tegoprazan + naproxen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tegoprazan + naproxen.